1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"International Research in Infectious Diseases (R01 Clinical Trial Not Allowed)" is currently closed and not accepting applications.
International Research in Infectious Diseases (R01 Clinical Trial Not Allowed) is sponsored by National Institute of Allergy and Infectious Diseases (NIAID). This funding opportunity supports high-priority, regionally relevant infectious disease research in resource-constrained countries.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Applicant organizations must be headquartered in non-U.S. resource-constrained countries. Confirm the full requirements in the official notice before applying.
The current listing shows up to $125,000 per year in direct costs, with a maximum of $625,000 in direct costs over a five-year project period. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was July 15, 2022, which has passed. Check the official notice for any future application windows before investing time in a proposal.
International Research in Infectious Diseases (R01 Clinical Trial Not Allowed) is funded by National Institute of Allergy and Infectious Diseases (NIAID). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articleThe ReVAMPP network funds vaccine and monoclonal antibody research across five virus families. Here is who won, what the prototype-pathogen strategy means, and how to position for the next round.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read article